Memapsin 2 (beta-secretase) inhibitors: drug development.

Curr Alzheimer Res

Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, USA.

Published: April 2008

Memapsin 2 (beta-secretase, BACE 1) processing of beta-amyloid precursor protein is the first step in the pathway leading to the production of amyloid-beta, thus, it is a major target for the development of inhibitor drug for the treatment of Alzheimers's Disease. Although there are distinctive advantages of this protease as a drug target, the development of drug-like memapsin 2 inhibitors has been somewhat slow since the cloning of the protease seven years ago. Here we review the progress of memapsin 2 inhibitor development using crystal structure-based design cycles. Recent progress has evolved the inhibitors into sizes sufficiently small to penetrate cell membranes and the blood-brain barrier yet retain potency for the inhibition of Abeta production in cultured cells and experimental animals. Such progress lends optimism that clinically useful memapsin 2 inhibitors will eventually be developed.

Download full-text PDF

Source
http://dx.doi.org/10.2174/156720508783954730DOI Listing

Publication Analysis

Top Keywords

memapsin beta-secretase
8
target development
8
memapsin inhibitors
8
memapsin
5
inhibitors
4
beta-secretase inhibitors
4
inhibitors drug
4
development
4
drug development
4
development memapsin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!